QBLINTRO
Live / Allowed — Published for opposition (as of 17 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 11 Jun 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99228718
- Mark type
- Stylized text
- Filed
- 11 Jun 2025
- Published for opposition
- 17 Feb 2026
- Attorney of record
- Elsa D. Lemoine
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations used for the treatment of cancer and immune diseases and conditions; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of lupus erythematosus, rheumatoid arthritis, multiple sclerosis, neuromyelitis optica and systemic sclerosis
Owner
- Amgen Inc., Thousand Oaks, CA, US
- Amgen Inc., Thousand Oaks, CA, US
Prosecution history
- 17 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Feb 2026 — PUBLISHED FOR OPPOSITION
- 11 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 22 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 21 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 21 Jan 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 28 Jul 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 28 Jul 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 26 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 26 Jul 2025 — NON-FINAL ACTION E-MAILED
- 26 Jul 2025 — NON-FINAL ACTION WRITTEN
- 26 Jul 2025 — ASSIGNED TO EXAMINER
- 11 Jun 2025 — APPLICATION FILING RECEIPT MAILED
- 11 Jun 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED